Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

42.34 +2.03 (+5.04%)

Streaming Delayed Price Updated: 2:57 PM EDT, Apr 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 31, 2025

Via Benzinga

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

March 31, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

3 Reasons to Sell CORT and 1 Stock to Buy Instead

March 26, 2025

Corcept currently trades at $58.76 and has been a dream stock for shareholders. It’s returned 434% since March 2020, blowing past the S&P 500’s 117% gain. The company has also beaten the index over the...

Via StockStory

Topics Stocks

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Exploring NASDAQ:CORT's high growth characteristics. ↗

January 15, 2025

Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) suited for high growth investing?

Via Chartmill

Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout. ↗

January 15, 2025

CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a strong growth stock, setting up for a breakout.

Via Chartmill

NASDAQ:CORT is not too expensive for the growth it is showing. ↗

January 10, 2025

For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.

Via Chartmill

CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock which is not overvalued. ↗

March 24, 2025

Uncover the potential of CORCEPT THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive...

Via Chartmill

3 Growth Stocks in Hot Water

March 19, 2025

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Via StockStory

1 Small-Cap Stock on Our Buy List and 2 to Avoid

March 14, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

March 10, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT). ↗

December 12, 2024

Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT).

Via Chartmill

NASDAQ:CORT, a strong growth stock, setting up for a breakout. ↗

December 12, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating.

Via Chartmill

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

March 04, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

March 04, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

March 03, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Why Corcept (CORT) Shares Are Sliding Today

February 27, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 9.3% in the pre-market session after the company reported weak fourth quarter results: its revenue missed significantly, and its EPS...

Via StockStory

Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings

February 26, 2025

Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 34.3% year on year to $181.9 million. On the other hand, the company’s...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

February 26, 2025

From Corcept Therapeutics

Via Business Wire

While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗

February 26, 2025

CORCEPT THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:CORT is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.

Via Chartmill

Corcept (CORT) Q4 Earnings Report Preview: What To Look For

February 25, 2025

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results tomorrow afternoon. Here’s what you need to know.

Via StockStory

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

February 12, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Looking for growth without the hefty price tag? Consider NASDAQ:CORT. ↗

January 31, 2025

CORCEPT THERAPEUTICS INC could be undervalued. NASDAQ:CORT is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.

Via Chartmill

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

December 30, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Investors should take note of NASDAQ:CORT, a growth stock that remains attractively priced. ↗

December 20, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) stands out as a growth opportunity that won't break the bank.

Via Chartmill

Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

December 16, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes ↗

December 13, 2024

Corcept Therapeutics reports positive Phase 4 CATALYST results, showing Korlym significantly improves hemoglobin A1c in hypercortisolism patients.

Via Benzinga

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

December 12, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

December 11, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.